Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.58 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2051705 | 0.86 | HSPA5 (0.52) | HSPA5ALDH1A1POLBMPOCYP2D6 | |
| SCHEMBL25173673 | 0.81 | SLC6A4 (0.58) | SLC6A4GBA1HRH4HRH3 | |
| SCHEMBL18726535 | 0.81 | HSPA5 (0.46) | HSPA5ALDH1A1POLBMPOCYP2D6 | |
| SCHEMBL386760 | 0.81 | HSPA5 (0.46) | HSPA5ALDH1A1POLBMPOCYP2D6 | |
| SCHEMBL11400538 | 0.80 | SLC6A4 (0.61) | SLC6A4GBA1MPOHRH3 | |
| SCHEMBL22444126 | 0.80 | CYP2D6 (0.56) | SLC6A4MPOCYP2D6TSHRHIF1A | |
| SCHEMBL28517671 | 0.80 | EED (0.56) | ALDH1A1POLBHRH4HRH3 | |
| SCHEMBL21800055 | 0.78 | GBA1 (0.56) | SLC6A4GBA1SLC6A2HRH4HRH3 | |
| SCHEMBL3966077 | 0.78 | GBA1 (0.56) | SLC6A4GBA1SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL6383375 | 0.78 | GBA1 (0.56) | SLC6A4GBA1SLC6A2HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2024251040-A1 | IRAK4 DEGRADATION AGENT AND USE THEREOF | 广州市联瑞制药有限公司 | 2024-12-12 | — | — | WO | disclosed |
| CN-113874080-B | IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-09-27 | — | — | CN | disclosed |
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | DICE MOLECULES SV, INC. | 2023-02-23 | — | — | US | disclosed |
| US-11447468-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3921038-A1 | IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021048241-A1 | RADIOLABELED COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-18 | — | — | WO | disclosed |
| WO-2020163554-A1 | IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | DICE MOLECULES SV, INC. | 2020-08-06 | — | — | US | disclosed |
| US-8716312-B2 | Inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2376454-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2367598-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224193-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| WO-2010107605-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010059611-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230053746-A1 | IL-17 LIGANDS AND USES THEREOF | IL17A, IL2, IL15 | SLC6A4 4880/4885GBA1 3236/4885HSPA5 4010/4885 |
| US-20110224193-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | SLC6A4 2307/4885GBA1 369/4885HSPA5 1417/4885 |
| US-11447468-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | SLC6A4 4880/4885GBA1 3236/4885HSPA5 4010/4885 |
| US-20200247785-A1 | IL-17 Ligands And Uses Thereof | IL17A, IL2, IL15 | SLC6A4 4880/4885GBA1 3236/4885HSPA5 4010/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | SLC6A4 4880/4885GBA1 3236/4885HSPA5 4010/4885 |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | SLC6A4 2524/4885GBA1 323/4885HSPA5 1439/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | SLC6A4 2415/4885GBA1 63/4885HSPA5 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.